Evidence map›Paper›PMID 35766866›Full record

ReviewInternational journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience2022

Could melatonin have a potential adjuvant role in the treatment of the lasting anosmia associated with COVID-19? A review.

Ellen M S Xerfan, Priscila K Morelhao, Felipe H Arakaki, Anamaria da Silva Facina, Jane Tomimori, Sandra D Xavier, Sergio Tufik, Monica L Andersen

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Could melatonin have a potential adjuvant role in the treatment of the lasting anosmia associated with COVID-19? A review.International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Ellen M S XerfanPrograma de Pós-Graduação em Medicina Translacional, Departamento de Medicina, Escola Paulista de Medicina, Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil.
Priscila K MorelhaoDepartamento de Psicobiologia, Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil.
Felipe H ArakakiDepartamento de Psicobiologia, Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil.
Anamaria da Silva FacinaDepartamento de Dermatologia, Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil.ORCID https://orcid.org/0000-0002-2888-7227
Jane TomimoriPrograma de Pós-Graduação em Medicina Translacional, Departamento de Medicina, Escola Paulista de Medicina, Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil.
Sandra D XavierDepartamento de Psicobiologia, Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil.
Sergio TufikDepartamento de Psicobiologia, Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil.
Monica L AndersenDepartamento de Psicobiologia, Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil.
Universidade Federal de São Paulo · BR

Funding

Associação Fundo de Incentivo à PesquisaConselho Nacional de Desenvolvimento Científico e TecnológicoCoordenação de Aperfeiçoamento de Pessoal de Nível Superior
6 · The paper itself

Abstract

introductionAnosmia, the loss of the sense of smell, is usually associated with rhinopathies and has been reported as a common symptom of COVID-19. There is no specific drug to treat this condition, although some evidence suggests that melatonin could promote the recovery of olfactory sensory neurons.

methodsWe set out to perform a narrative review to synthesize the current evidence in this area in respect of our hypothesis that melatonin may be linked with anosmia and play a part in oxidative stress and the regulation of inflammation. The main electronic databases (MEDLINE/PubMed, Embase, and Cochrane) were searched.

resultsThe search produced 26 articles related to our hypothesis. Some studies examined issues related to melatonin's effects and its use as adjuvant therapy for COVID-19. Despite some studies suggesting that melatonin may have potential in the treatment of COVID-19, to the best of our knowledge, there have been no trials that have used it to treat anosmia associated with the disease. Few articles identified proposed that melatonin might have an effect on olfactory cells. DISCUSSION: Further experimental and clinical research on the role of circadian melatonin in the olfactory system is warranted. This will provide evidence of the use of melatonin in the management of anosmia. A number of identified studies suggest that the imbalanced release of melatonin by the pineal gland associated with sleep disturbance may play a role in anosmia, although the specific pathway is not yet entirely clear. This may be a base for further research into the potential role of melatonin as adjuvant treatment of anosmia.

Indexed as

COVID-19MelatoninAnosmiaHumansOxidative StressMelatoninanosmiacircadian rhythmCOVID-19melatoninolfactory functionsleep

Identifiers

PMID35766866
PMCPMC9349376
OpenAlexW4283737107

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.